Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ESWI 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) today announced it will present data from six company-sponsored studies...

Related Keywords

United States ,America ,Ashley Georgian ,Jennifer Mcintyre ,Asia Pacific ,None Of The Janssen Pharmaceutical Companies ,Drug Administration ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,Companies Of Johnson ,European Scientific Working Group On Influenza ,Johnson ,Eighth European Scientific Working Group ,Penny Heaton ,Global Therapeutic Area Head ,Janssen Research ,F Based Vaccine ,Lower Respiratory Tract Disease ,Reduces Symptom Severity ,Vaccine Recipients With ,Regimen Selection ,Adaptive Design Phase ,Adults Aged ,Between Patient Reported ,Case Definition ,Capture Moderate To Severe ,Respiratory Syncytial Virus ,Infected Adults ,Meaningful Within Patient Change Thresholds ,Respiratory Infection Intensity ,Impact Questionnaire ,North America ,Breakthrough Therapy Designation ,European Medicines Agency ,Medicinal Products ,Human Use ,Latin America ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Janssen Pharmaceutical Companies Of Johnson Amp ,